Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ophth. Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ophth. Other
    Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study - (BMJ)
    First Gene Associated With Dry Age-Related Macular Degeneration Found - (DGNews)
    NICE Final Guidance on Ranibizumab, Pegaptanib for Age-Related Macular Degeneration - (DGNews)
    Laser Superior to Corticosteroids in Diabetic Macular Edema - (DGNews)
    Sandoz Timolol Ophthalmic Solution Recalled Due to Potential Health Risk - (DGNews)

    News archive

     Recent webcasts/CME - Ophth. Other
      Update on the Pathophysiology, Molecular Biology, and Treatment of Macular Edema
      Newer Approaches to the Long-Term Management of Dry Eye Disease
      Global Perspectives on Diabetic Retinopathy: More Than Meets the Eye
      New Insights in Macular Edema: Understanding and Evaluating Treatment Strategies
      Update on Age-related Macular Degeneration: What Does the Comprehensive Ophthalmologist Need to Know?

      Webcasts/CME archive

       Recent cases - Ophth. Other
        Metastatic Non-Small Cell Lung Cancer Presenting with an Orbital Metastasis: A Case Report
        Infraorbital Cutaneous Angiosarcoma: A Diagnostic and Therapeutic Dilemma
        Lateral Rectus Muscle Disinsertion and Reattachment to the Lateral Orbital Wall in Exotropic Duane Syndrome: A Case Report
        Choroidal Neovascularisation Secondary to Rubella Retinopathy
        Solitary Fibrous Tumor of the Orbit: Case Report and Review of Immunohistochemical Staining

        Cases archive
          




        my personal edition > ophth. other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Fermavisc Found Effective For Dry Eye

        A DGReview of :"A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome."
        Eye

        10/10/2002
        By Mark Moran


        A 0.1% (w/v) solution of sodium hyaluronate, applied topically three or four times a day as needed, appears to be effective for relief of symptoms of dry eye.

        The solution also appears to have a protective effect on the corneal epithelium. This is evidenced by a reduction in the level of staining of corneal epithelial cells by rose bengal, say researchers with VitroLife UK Ltd., of Edinburgh, England.

        They compared 0.1% solution of sodium hyaluronate (HA, Fermavisc) with a 1.4% (w/v) solution of polyvinyl alcohol in a randomised, crossover, multicentre trial carried out at eight centres in the United Kingdom.

        Thirty-nine patients were enrolled in the study; of these, 32 completed it. They were randomised to one of the treatment arms for four weeks, then crossed over to the other study product. Burning and grittiness were assessed by visual analogue scale (VAS) at each study visit and other objective clinical assessments of ocular structure and function were carried out at baseline and the end of each treatment period.

        After treatment with HA, patients' VAS score for burning was significantly improved (P = 0.03), and the rose bengal staining score was significantly lower (P = 0.04).

        "This study confirms that Fermavisc is a safe and effective product for use in the alleviation of symptoms of severe dry eye syndrome," the researchers conclude.
        Eye 2002 Sep;16(5):601-7. "A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send